About Us
About Dynamic Cell Therapies (DCT)
Dynamic Cell Therapies (DCT) is an exciting venture funded emerging cell therapy company developing controllable chimeric antigen receptor (CAR) T cells for cancer immunotherapy, based on a transformative technology developed in the laboratory of Dr. Carl Novina at the Dana-Farber Cancer Institute. Launched in the Pagliuca Harvard Life Lab incubator, DCT has recently moved to Watertown, MA and has recently closed an investment from Atossa Therapeutics, a clinical-stage, publicly-traded company (ATOS). DCT is supported by an impressive team of scientific, clinical and business advisors.
Dynamic Cell Therapies is developing controllable CAR T cells to address difficult-to-treat cancers. Our platform technology of dynamic control of engineered T cells will improve the safety, efficacy, and durability of CAR T cell therapies. This system will have immediate applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases.
Our Pipeline
We are dedicated to developing cells to tackle difficult-to-treat cancers. Our team of experts works tirelessly to advance cell therapies and bring hope to patients who need it most.
We strive to innovate and improve treatment options by leveraging cutting-edge research and technology. At Dynamic Cell Therapies, our goal is to make a meaningful impact on the fight against cancer.
